Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometry
Favipiravir and remdesivir are drugs to treat COVID-19. This study aims to find an optimum and validated method for simultaneous analysis of favipiravir and remdesivir in Volumetric Absorptive Microsampling (VAMS) by Ultra High-Performance Liquid Chromatography–Tandem Mass Spectrophotometry. The use...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1022605/full |
| _version_ | 1797830474857447424 |
|---|---|
| author | Yahdiana Harahap Yahdiana Harahap Roesytas Fitria Noer Timbul Partogi H. Simorangkir |
| author_facet | Yahdiana Harahap Yahdiana Harahap Roesytas Fitria Noer Timbul Partogi H. Simorangkir |
| author_sort | Yahdiana Harahap |
| collection | DOAJ |
| description | Favipiravir and remdesivir are drugs to treat COVID-19. This study aims to find an optimum and validated method for simultaneous analysis of favipiravir and remdesivir in Volumetric Absorptive Microsampling (VAMS) by Ultra High-Performance Liquid Chromatography–Tandem Mass Spectrophotometry. The use of VAMS can be an advantage because the volume of blood is small and the sample preparation process is simple. Sample preparation was done by precipitation of protein using 500 μL of methanol. Analysis was carried out by ultra high-performance liquid chromatography–tandem mass spectrophotometry with ESI+ and MRM with m/z 157.9 > 112.92 for favipiravir, 603.09 > 200.005 for remdesivir, and at m/z 225.968 > 151.991 for acyclovir as the internal standard. The separation was carried out using an Acquity UPLC BEH C18 column (100 × 2.1 mm; 1.7 m), 0.2% formic acid—acetonitrile (50:50), flow rate was 0.15 mL/min, and column temperature was 50°C. The analytical method has been validated with the requirements issued by the Food and Drug Administration (2018) and European Medicine Agency (2011). The calibration range of favipiravir is 0.5–160 μg/mL and 0.002–8 μg/mL for remdesivir. |
| first_indexed | 2024-04-09T13:36:41Z |
| format | Article |
| id | doaj.art-e6daeb6633a84bffb8df8bf4eca5c956 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-09T13:36:41Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-e6daeb6633a84bffb8df8bf4eca5c9562023-05-09T09:45:45ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-05-011010.3389/fmed.2023.10226051022605Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometryYahdiana Harahap0Yahdiana Harahap1Roesytas Fitria Noer2Timbul Partogi H. Simorangkir3Faculty of Pharmacy, Universitas Indonesia, Depok, IndonesiaPharmacy Study Program, Faculty of Medicine and Health Sciences, the Republic of Indonesia Defense University, Bogor, IndonesiaFaculty of Pharmacy, Universitas Indonesia, Depok, IndonesiaPharmacy Study Program, Faculty of Medicine and Health Sciences, the Republic of Indonesia Defense University, Bogor, IndonesiaFavipiravir and remdesivir are drugs to treat COVID-19. This study aims to find an optimum and validated method for simultaneous analysis of favipiravir and remdesivir in Volumetric Absorptive Microsampling (VAMS) by Ultra High-Performance Liquid Chromatography–Tandem Mass Spectrophotometry. The use of VAMS can be an advantage because the volume of blood is small and the sample preparation process is simple. Sample preparation was done by precipitation of protein using 500 μL of methanol. Analysis was carried out by ultra high-performance liquid chromatography–tandem mass spectrophotometry with ESI+ and MRM with m/z 157.9 > 112.92 for favipiravir, 603.09 > 200.005 for remdesivir, and at m/z 225.968 > 151.991 for acyclovir as the internal standard. The separation was carried out using an Acquity UPLC BEH C18 column (100 × 2.1 mm; 1.7 m), 0.2% formic acid—acetonitrile (50:50), flow rate was 0.15 mL/min, and column temperature was 50°C. The analytical method has been validated with the requirements issued by the Food and Drug Administration (2018) and European Medicine Agency (2011). The calibration range of favipiravir is 0.5–160 μg/mL and 0.002–8 μg/mL for remdesivir.https://www.frontiersin.org/articles/10.3389/fmed.2023.1022605/fullfavipiravirremdesivirVAMSLC-MS/MSCOVID-19acyclovir |
| spellingShingle | Yahdiana Harahap Yahdiana Harahap Roesytas Fitria Noer Timbul Partogi H. Simorangkir Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometry Frontiers in Medicine favipiravir remdesivir VAMS LC-MS/MS COVID-19 acyclovir |
| title | Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometry |
| title_full | Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometry |
| title_fullStr | Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometry |
| title_full_unstemmed | Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometry |
| title_short | Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometry |
| title_sort | development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high performance liquid chromatography tandem mass spectrophotometry |
| topic | favipiravir remdesivir VAMS LC-MS/MS COVID-19 acyclovir |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1022605/full |
| work_keys_str_mv | AT yahdianaharahap developmentandvalidationofmethodforanalysisoffavipiravirandremdesivirinvolumetricabsorptivemicrosamplingwithultrahighperformanceliquidchromatographytandemmassspectrophotometry AT yahdianaharahap developmentandvalidationofmethodforanalysisoffavipiravirandremdesivirinvolumetricabsorptivemicrosamplingwithultrahighperformanceliquidchromatographytandemmassspectrophotometry AT roesytasfitrianoer developmentandvalidationofmethodforanalysisoffavipiravirandremdesivirinvolumetricabsorptivemicrosamplingwithultrahighperformanceliquidchromatographytandemmassspectrophotometry AT timbulpartogihsimorangkir developmentandvalidationofmethodforanalysisoffavipiravirandremdesivirinvolumetricabsorptivemicrosamplingwithultrahighperformanceliquidchromatographytandemmassspectrophotometry |